newsfilter
← Latest News
GlobeNewswire·

Crescent Biopharma Announces Grants of Inducement Awards

  • Crescent Biopharma's Compensation Committee approved equity inducement awards on May 11, 2026, granting options to purchase 129,075 ordinary shares to five non-executive employees.
  • The grants were approved under the Company's 2025 Employment Inducement Incentive Award Plan & were material to each employee's acceptance of employment per Nasdaq Listing Rule 5635(c)(4).
  • Each option has a 10-year term with an exercise price of $18.52, matching the closing share price on May 11, 2026.
  • Vesting begins with one-fourth of shares exercisable on the first anniversary of the start date, followed by monthly vesting of one-forty-eighth of shares thereafter, contingent on continuous service.
  • Crescent Biopharma is a clinical-stage oncology company developing a PD-1 x VEGF bispecific antibody & novel antibody-drug conjugates (ADCs) for solid tumors.